echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > New anti-inflammatory drugs! Lilly IL-17A inhibitor Taltz Psytopic Arthritis (PsA) Head-to-Head Phase III Study Efficacy Beats Humira

    New anti-inflammatory drugs! Lilly IL-17A inhibitor Taltz Psytopic Arthritis (PsA) Head-to-Head Phase III Study Efficacy Beats Humira

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    , June 08, 2020 /PRNewswireBio ValleyBIOON/--Lilly(Eli Lilly) recently announced the results
    of The New Analysis of The European Union of Rheumatology (EULAR) ElectronicGroup 2020 at the 2020 E-
    ConferenceSPIRIT-H2H is the first large-scale head-to-head (H2H) superiority study to treat PsA, and the first to label and dose Taltz and Shumita (Humira, Adamum monotag) and allow the simultaneous inclusion of conventional disease-modified anti-rheumatic therapy (csDMARD) therapyBased on previously published results, Taltz was the first IL-17A antagonist to outperform Humira in PsA head-to-head studiesnew data released this year show that Taltz has strong efficacy as a monodrug treatment or as a combination of methotrexate (MTX) or other csDMARD, further confirming the continued efficacy and long-term potential of Taltz's first-line active PsASPIRIT-H2H was a multicenter, random, open-label, parallel group study of 566 active PsA patients who had not previously received biological DMARD treatment, with a body surface area of at least 3% and insufficient response to at least one conventional DMARD, and evaluated the efficacy and safety of Taltz versus Humira for 52 weeksIn the study, patients were randomly assigned to the approved dose of Taltz (160 mg starting dose, followed by 80 mg every 4 weeks) and Humira (40 mg every 2 weeks) for 52 weeksThe main efficacy analysis was carried out at week 24PsA patients who also met the criteria for moderate to severe plaque psoriasis received an approved dose of Taltz (starting dose 160 mg, 80 mg every 2 weeks at 2-12 weeks, followed by 80 mg every 4 weeks) or Humira (80 mg starting dose, followed by a 2 weeks of 40 mg from the initial dose)The study's main endpoint was the 24th week of simultaneously achieving the proportion of patients who simultaneously improved active PsA symptoms and signs (using ACR50 evaluation) and skin plaque removal (using PASI100 evaluation), an innovative approach designed to comprehensively measure clinical improvementacross across multiple psA domainsThe key secondary endpoint is to demonstrate The non-disadvantageof ity of Taltz relative to Humira in the ACR50 and the superiority in paSI100- 24 weeks of results showed thatstudies reached the primary and all critical secondary endpointsIn terms of primary endpoint, during the 24th week of treatment, the proportion of patients in the Taltz group who reached both ACR50 and PASI100 was significantly higher than in the Humira group (36% vs 28%, p 0.05)Taltz also reached a critical secondary endpoint, including non-disadvantaged efficacy (51% vs 47%; 95% CI (-4.3%, 12.1%), non-poor boundary: -12.0%), and THE superiority of the paSI100 patient ratio (60% vs 47%, p.01)- 52 weeks show results:In 39% of the patients in the Taltz treatment group, joint and skin improvement (ACR50 and PASI100) occurred at the same time, compared with 26% in the Humira treatment groupIn addition, in the 52nd week of treatment, Taltz performed at least as well as Humira at multiple secondary endpoints, including: (1) ACR50: Week 52, the proportion of patients in the Taltz treatment group and the Humira treatment group who reached ACR50 was 50%, 50% ;(2) ACR70: In the 52nd week of treatment, the proportion of patients in the Taltz treatment group and Humira treatment group reaching ACR70 was 35%, 34% ;(3) PASI100: in the 52nd week of treatment, the proportion of patients in the Taltz treatment group and the Humira treatment group reached PASI100, 64%, and 41%, respectively- EULAR-recently published pre-specified analysis:compared the efficacy of Taltz and Humira in patients treated with monodrug therapy, combined MTX, combined MTX, and another conventional synthetic disease modified anti-rheumatic drug (csDMARD, including lyse sulphate, cyclosporine, lefoframet)The 52-week results showed that Taltz showed improvement in multiple endpoints compared to Humira, whether combined with MTX or other csDMARDin the single-drug treatment subgroup, Taltz had a higher proportion of patients with the lowest degree of disease activity (49% vs 33%), but Taltz and Humira had similar MDA remission rates in the combined MTX treatment subgroup (47% vs 47%) and the joint csDMARD subgroup (47% vs 44%)MDA is an endpoint that includes at least 5 of the seven rheumatic outcome indicators, and is the treatment goal of several professional organizationsin all three subgroups, a higher proportion of patients treated with Taltz reached the primary endpoint of ACR50 and PASI100 at the same time at the 52st week: (1) single drug therapy, 38 percent of the Taltz group, 19 percent ;(2) combined with MTX therapy, 39 percent of the Taltz group, 30 percent ;(3) joint csDDd treatment group, and Talsdm3patients treated by Taltz had a higher proportion of PASI100 in single-drug treatment (66% vs 35%), combined MTX treatment (63% vs 44%) or combined csDMARD treatment (64% vs 44%) The proportion of patients treated by Taltz and Humira reached ACR50, whether it was single-drug treatment (51% vs 42%), combined MTX treatment (48% vs 56%) or combined csDMARD treatment (49% vs 53%)"Subgroup analysis of the SPIRIT-H2H study confirmed that Taltz was better than Humira at multiple PsA endpoints in single-drug therapy, and at least as effective when used in combination with MTX or other csDMARD," said Josef Smolen, a professor at the Medical University of Vienna and the first author of thesummary of the meeting Head-to-head study will provide important research for doctors when making treatment decisions, and the results of this subgroup analysis reinforce Taltz's efficacy in PsA patients with inadequate response to csDMARD "
    the safety of Taltz observed in the SPIRIT-H2H study was consistent with that reported in patients with moderate-severe plaque psoriasis (PsO) and PsA Lilly also published the results of two other studies THE SPIRIT-P2 STUDY SHOWED THAT IN PSA PATIENTS WHO RESPONDED INSUFFICIENTLY OR INTOLERANT PSA WITH A
    TUMORS, TALTZ THERAPY CONTINUOUSLY IMPROVED PSA'S SYMPTOMS AND SIGNS (ASSESSED ACCORDING TO THE ACR RESPONSE) AND PSA PERFORMANCE (INCLUDING END-OF-THE-LINE INFLAMMATION, FINGER INFLAMMATION, AND SKIN OUTCOMES) FOR UP TO 3 YEARS In A Stage III COAST-X study of patients with axial spinal arthritis (nr-axSpA) in active non-radiology, patients treated with Taltz observed improvements in fatigue, spinal pain, and stiffness at the 16th week In both studies, Taltz's security profile was consistent with previously reported results and no unexpected safety signals were found Dr Lotus Mallbris, Vice President of immunology Development at Lilly , said: "To date, Taltz has reported positive results from five head-to-head (H2H) superior studies in the treatment of PsA and PsO, including SPIRIT-H2H, IXORA-S, TYPE-2, BASED-based-3 and IXORA-R, and we are pleased to share additional data from THE SPIRIT-H2H subgroup analysis, which provides further evidence of Taltz's treatment as a single-drug treatment The comprehensive Taltz data provided on EULAR enhances Taltz's efficacy in treating PsA and axSpA patients "
    Taltz is a new anti-inflammatory drug developed Lilly , a monoclonal antibody that selectively binds cytofactor leukin 17A (IL-17A) and inhibits its interaction with the IL-17 receptor, without the cytokine IL-17B, IL-17C, IL-17D, IL-17E or IL-17F IL-17A is a naturally occurring cytokine that participates in normal inflammatory and immune responses Taltz inhibits the release of tetor cytokines and chemofactors in the U.S., Taltz was first approved in March 2016 as the second U.S.-listed IL-17
    A monoantidrug after Novartis heavy anti-inflammatory drug, Csentyx( To date, Taltz has been approved for 5 indications: (1) for the treatment of moderate to severe plaque psyritus (PsO) paediatric patients (under 6 to 18 years of age) and adult patients suitable for system therapy or phototherapy; Also known as radioactive mid-axis spinal arthritis (r-axSpA) adult patients, (4) for the treatment of moderate to severe plaque psoriasis patients (6 to 18 years of age ;() for the treatment of active non-radiology of axial spinal arthritis (nr-axSpA) patients with objective signs of inflammation the industry is bullish on Taltz's business prospects, with evaluate, a pharmaceutical market research firm, forecasting sales of $2.707 billion in 2024 (BioValley original source: EULAR 2020: Lilly's Taltz ® (ixekizumab) Continues to Show Robust and Continue And Ingacy in Psoria Arthrititics
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.